A recent study demonstrated that CD8+ T cells deficient in both PD-1 and LAG-3 exhibited enhanced tumor clearance and improved long-term survival compared to those lacking either PD-1 or LAG-3 alone. The gene discussed is CD8A; the disease is neoplasm.